Neither astaxanthin nor yoga produced the biggest drop in depression scores in a new trial of postmenopausal women. The combination did: a 45.1% reduction on the Hamilton Depression Rating Scale (HAM-D) over 12 weeks. Yoga alone managed 28.5%, and astaxanthin alone just 10.9%. The randomized controlled trial, published in Explore in 2026, is small and has real limits. It is still one of the more interesting recent attempts to pair a supplement with a movement practice for menopause-related mood symptoms.
What the researchers did
Abdulrahman and Abdullah, both affiliated with Akre Obstetrics and Gynecology Hospital in Kurdistan, Iraq, enrolled 100 sedentary postmenopausal women aged 55 to 60 with mild-to-moderate depressive symptoms. Participants were randomly assigned to one of four arms for 12 weeks:
- Control group (CG)
- Hatha yoga group (HYG): 75-minute sessions, three times weekly
- Astaxanthin group (ASG): 12 mg per day
- Combined group (HYASG): Hatha yoga plus 12 mg per day of astaxanthin
The yoga program covered āsana (postures), prāṇāyāma (breathing), relaxation and brief meditation. Outcomes included depression (HAM-D), menopause symptom severity (Menopause Rating Scale, MRS), menopause-specific quality of life (MENQOL), blood markers of oxidative stress, and peripheral-blood gene expression of SIRT1, PGC-1α and NRF1.
The numbers, arm by arm
The paper reports significant group × time interactions for all major outcomes (p < 0.001). That means the groups changed differently over the 12 weeks.
| Arm | HAM-D reduction |
|---|---|
| Yoga + astaxanthin | 45.1% |
| Yoga alone | 28.5% |
| Astaxanthin alone | 10.9% |
In the combined arm, MRS scores fell 41.1% and MENQOL scores fell 50.0%. The abstract does not give equivalent per-arm percentages for those two scales in the other groups, so the combination's margin on them can't be stated here.
The pattern suggests the effects weren't simply additive. Yoga did most of the work on mood, and astaxanthin alone had a modest effect. Together they produced the largest improvement, which the authors describe as greater than either intervention alone.
The biology: antioxidant enzymes and mitochondrial signals
Menopause is linked to oestrogen deficiency, oxidative stress and mitochondrial dysfunction, and the trial was built around that framing. Astaxanthin is a fat-soluble carotenoid antioxidant, so the oxidative-stress panel was a logical measurement.
Antioxidant status. The combined group had the largest increases in total antioxidant capacity (TAC), superoxide dismutase (SOD) and catalase (CAT) activity. It also had the greatest reductions in the lipid-peroxidation markers malondialdehyde (MDA) and TBARS.
Mitochondria-related gene expression. Measured by qRT-PCR in peripheral blood:
- SIRT1 and PGC-1α rose significantly in both yoga-containing groups. Based on the abstract, the signal came from yoga rather than from astaxanthin alone.
- NRF1 upregulation was most pronounced in the combined group. This is where the pairing seems to add something beyond yoga.
SIRT1, PGC-1α and NRF1 are tied to mitochondrial biogenesis and cellular energy regulation. That makes them plausible mechanistic candidates. This trial doesn't show that these shifts caused the mood improvements, only that they moved alongside them.
Honest caveats
Several limits matter before anyone treats this as a protocol.
- Blinding is likely limited. Yoga can't be blinded, and mood scales are sensitive to expectation and to the attention and social contact of a group program. The abstract doesn't say whether the astaxanthin was placebo-controlled. Check the full text before assuming the supplement effect was blinded.
- Likely single-center. The authors are from one hospital in Iraq, and the abstract describes no multi-site recruitment. Results may not generalize to other populations, diets or healthcare settings.
- Narrow population. Participants were sedentary women aged 55 to 60 with mild-to-moderate symptoms. The findings say nothing about severe depression, younger perimenopausal women or active women.
- Short duration. The trial ran 12 weeks, and the abstract reports no long-term follow-up.
- Surrogate markers. The gene expression data come from peripheral blood, not brain or muscle tissue. Serum oxidative-stress markers are indirect indicators.
- Small sample. One hundred women across four arms is modest, and the effect sizes should be confirmed in larger, independent trials.
This is not a substitute for treatment. Depression in menopause can be serious, and anyone with significant symptoms should work with a clinician. The study's own conclusion is hedged: the combination was associated with greater improvements.
Practical takeaways
Dose: The trial used 12 mg per day of astaxanthin for 12 weeks.
Timing: The abstract doesn't specify meal timing. As general guidance rather than a finding from this paper, astaxanthin is fat-soluble, and taking it with a meal containing some fat is the usual advice for absorption.
Yoga: The program was three sessions a week of about 75 minutes, combining postures, breathing, relaxation and brief meditation. Of the two components, yoga showed the larger standalone effect.
Who it might suit: Sedentary postmenopausal women with mild-to-moderate low mood who want a non-drug option to discuss with their doctor. It is not a replacement for medical care. Check with a clinician first if you take blood thinners or other medications, or have other health conditions.
Bottom line
If you take one thing from this trial, make it the yoga: it carried most of the mood benefit and drove the SIRT1 and PGC-1α changes. Astaxanthin looks like a possible add-on that nudged oxidative-stress and NRF1 outcomes further. Larger, blinded, multi-center trials with longer follow-up will show whether that edge holds up.